Natural killer cell ligand (NK cell ligand)

Natural killer (NK) cell ligands are a heterogeneous group of cell surface molecules that regulate the cytotoxic activity of NK cells by binding to various activating and inhibitory receptors. In malignant or infected cells, the expression profile of these ligands is often altered; for instance, 'stress-induced' activating ligands such as MICA, MICB, and ULBPs are upregulated to signal distress to the immune system via the NKG2D receptor (Shimasaki et al., 2020, Nature Reviews Drug Discovery). Conversely, many tumors downregulate MHC class I molecules to evade T-cell recognition, a phenomenon known as 'missing-self' that normally triggers NK cell activation, or they overexpress inhibitory ligands like HLA-E to suppress NK cell function through the NKG2A receptor (Vivier et al., 2012, Science). Therapeutic strategies targeting these ligands include monoclonal antibodies that block inhibitory checkpoints, bispecific innate cell engagers (BiKEs) that bridge NK cells to tumor ligands, and CAR-NK cells engineered to recognize specific stress ligands (Long et al., 2013, Annual Review of Immunology). This target entry is classified as incorrect because it represents a broad functional category of diverse molecules rather than a single, specific therapeutic target.

Other names

NK cell activating ligandsNK cell inhibitory ligandsStress-induced ligandsNKG2D ligandsMHC class I-related moleculesNatural killer cell receptor ligands

Modulation of NK cell activity by either blocking inhibitory interactions (e.g., KIR, NKG2A) to release the 'brakes' on the immune system or enhancing activating signals (e.g., NKG2D, NKp30) to promote the targeted lysis of malignant or infected cells.